Table 1 Key clinical data in the model
Parameters | Cabazitaxel | ASTI | Reference |
|---|---|---|---|
Weibull parameters | |||
Scale (λ) for PFS | 0.034827 | 0.069115 | [19] |
Shape (γ) for PFS | 1.486146 | 1.468545 | [19] |
Scale (λ) for OS | 0.007118 | 0.007698 | [19] |
Shape (γ) for OS | 1.676228 | 1.867383 | [19] |
Survival | |||
Median OS (range), month | 13.6 (11.5–17.5) | 11.0 (9.2–12.9) | [19] |
Median imaging PFS (range), month | 8.0 (5.7–9.2) | 3.7 (2.8–5.1) | [19] |
Median PFS (range), month | 4.4 (3.6–5.4) | 2.7 (2.4–2.8) | [19] |
Treatment | |||
Median treatment duration (range), month | 22 (3–88) | 12.5 (2–141) | [19] |
Median treatment cycles | 7 (1–29) | 4 (1–45) | [19] |
Probability of AEs (grade 3/4) | |||
Musculoskeletal pain or discomfort | 0.016 (0.013–0.019) | 0.056 (0.045–0.067) | [19] |
Renal disorder | 0.032 (0.026–0.038) | 0.081 (0.065–0.097) | [19] |
Anemia | 0.080 (0.064–0.096) | 0.048 (0.038–0.058) | [19] |
Leukopenia | 0.320 (0.256–0.384) | 0.016 (0.013–0.019) | [19] |
Neutropenia | 0.447 (0.358–0.536) | 0.032 (0.026–0.038) | [19] |
Utility | |||
PFS | 0.617 (0.494–0.740) | 0.617 (0.494–0.740) | [22] |
PD | 0.370 (0.296–0.444) | 0.370 (0.296–0.444) | [22] |